[HTML][HTML] Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/enzalutamide versus anti-androgen receptor ASC-J9® …
TH Lin, SO Lee, Y Niu, D Xu, L Liang, L Li… - Journal of biological …, 2013 - ASBMB
Despite the fact that androgen deprivation therapy (ADT) can effectively reduce prostate
cancer (PCa) size, its effect on PCa metastasis remains unclear. We examined the existing
data on PCa patients treated with ADT plus anti-androgens to analyze ADT effects on
primary tumor size, prostate-specific antigen (PSA) values, and metastatic incidence. We
found that the current ADT with anti-androgens might lead to primary tumor reduction, with
PSA decreased yet metastases increased in some PCa patients. Using in vitro and in vivo …
cancer (PCa) size, its effect on PCa metastasis remains unclear. We examined the existing
data on PCa patients treated with ADT plus anti-androgens to analyze ADT effects on
primary tumor size, prostate-specific antigen (PSA) values, and metastatic incidence. We
found that the current ADT with anti-androgens might lead to primary tumor reduction, with
PSA decreased yet metastases increased in some PCa patients. Using in vitro and in vivo …